Cargando…

A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β(2)-adrenergic agonist, in asthma; a Phase II, randomized study

BACKGROUND: Long-acting β(2)-adrenergic agonists (LABAs) are recommended in combination with inhaled corticosteroids (ICSs) for asthma management. Abediterol is a novel, selective, potent, once-daily LABA in development for treatment of asthma and chronic obstructive pulmonary disease. This study ai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Dave, Pujol, Helena, Ribera, Anna, Seoane, Beatriz, Massana, Eric, Astbury, Carol, Ruiz, Sandrine, de Miquel, Gonzalo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320624/ https://www.ncbi.nlm.nih.gov/pubmed/25398689 http://dx.doi.org/10.1186/1471-2466-14-176

Ejemplares similares

Abediterol, a novel long-acting β(2)-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
por: Beier, Jutta, et al.
Publicado: (2016)

Efficacy, safety, and tolerability of once‐daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7‐day, crossover study
por: Beier, Jutta, et al.
Publicado: (2017)

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
por: Jimenez, Eulalia, et al.
Publicado: (2020)

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
por: Singh, Dave, et al.
Publicado: (2020)

Anxiolytics for Bronchodilation: Refinements to GABA(A) Agonists for Asthma Relief
por: Nayak, Ajay P., et al.
Publicado: (2022)

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?
por: Price, David, et al.
Publicado: (2014)

Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial
por: Haney, Sarah, et al.
Publicado: (2005)

Short-acting β2-agonists (SABA) bronchodilator sales and outdoor mould in central France
por: Caillaud, D. M., et al.
Publicado: (2019)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
por: Singh, Dave, et al.
Publicado: (2019)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies
por: Balaguer, Victor, et al.
Publicado: (2020)

Beta-Adrenergic Agonists
por: Barisione, Giovanni, et al.
Publicado: (2010)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study
por: Molina, Jesús, et al.
Publicado: (2023)

Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality
por: Salpeter, Shelley R
Publicado: (2007)

The future of bronchodilation: looking for new classes of bronchodilators
por: Cazzola, Mario, et al.
Publicado: (2019)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

Latrophilin receptors: novel bronchodilator targets in asthma
por: Faiz, A, et al.
Publicado: (2017)

Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients
por: Labuda, Malgorzata, et al.
Publicado: (2011)

Effect of β(2)-adrenergic receptor gene (ADRB2) 3′ untranslated region polymorphisms on inhaled corticosteroid/long-acting β(2)-adrenergic agonist response
por: Ambrose, Helen J, et al.
Publicado: (2012)

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
por: Donohue, James F, et al.
Publicado: (2011)

Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators
por: Nicolini, Antonello
Publicado: (2012)

Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2013)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: a pilot study
por: Voduc, Nha, et al.
Publicado: (2012)

Agonist-Directed Desensitization of the β(2)-Adrenergic Receptor
por: Goral, Vasiliy, et al.
Publicado: (2011)

Altered pharmacological effects of adrenergic agonists during hypothermia
por: Dietrichs, Erik Sveberg, et al.
Publicado: (2016)

β-agonists for ARDS: the dark side of adrenergic stimulation?
por: Thompson, B Taylor
Publicado: (2012)

Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices
por: Donovan, Chantal, et al.
Publicado: (2014)

Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity
por: Bosak, Anita, et al.
Publicado: (2017)

Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
por: Rhee, Chin Kook, et al.
Publicado: (2019)

The paradoxical response to short-acting bronchodilator administration in patients with chronic obstructive pulmonary disease
por: Shin, Hong-Joon, et al.
Publicado: (2021)

Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
por: Chin, Pik-Qi, et al.
Publicado: (2022)

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
por: Singh, Dave, et al.
Publicado: (2022)

Agemone mexicana flavanones; apposite inverse agonists of the β2-adrenergic receptor in asthma treatment
por: Eniafe, Gabriel O., et al.
Publicado: (2018)

The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor
por: Warne, Tony, et al.
Publicado: (2011)

Feasibility of Deploying Inhaler Sensors to Identify the Impacts of Environmental Triggers and Built Environment Factors on Asthma Short-Acting Bronchodilator Use
por: Su, Jason G., et al.
Publicado: (2016)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jrgutm7knfkic5vq3uituibvme